News

Press release: Uppsala, August 21, 2019. Dicot AB (publ), developer of drugs targeting sexual dysfunction, today announced that Göran Beijer, CEO, will participate and host one-on-one investor meetings at the following upcoming investor conferences: BioStock Live Capital Markets Day and the LSX Nordic Congress 2019.

The shareholders in Dicot AB (publ) reg. no. 559006-3490 (the "Company") are hereby convened to the extraordinary general meeting on Thursday, August 22, 2019, at 3 p.m. at Advokatfirman Lindahl's office at Vaksalagatan 10 in Uppsala.

Dicot AB ("Dicot" or "the Company") has today on July 23, 2019 resolved to issue units, consisting of shares and warrants, with preferential rights for the Company"s existing shareholders, conditional on the Extraordinary General Meeting's subsequent approval and that the Extraordinary General Meeting resolves to amend the Company"s Articles of Association regarding the number of shares and share capital ("Rights Issue"). In connection with the Rights Issue, Dicot has entered into an agreement regarding a short-term bridge loan of SEK 4 million ("The Bridge Loan").

(The previous press release was sent out at 17.40 and has been updated with the correct date. Nothing else differs from the previous press release.)

Press release: Uppsala, July 18, 2019. Dicot AB (publ), developer of drugs targeting sexual dysfunction, today announced that the company has received a grant of SEK 100,000 from Vinnova"s program "IP-checks Q2 2019" for Intellectual Property Review by Dicot AB.

Press release: Uppsala, June 18, 2019. Dicot AB (publ), developer of drugs targeting sexual dysfunction, today announced that the company has received a grant of SEK 100,000 from Vinnova"s program "IP-checks Q2 2019" for Intellectual Property Review by Dicot AB.

Press release: Uppsala, June 25, 2019. Dicot AB (publ, developer of drugs targeting sexual dysfunction, today announced that the company has contracted Julie Silber as its new CFO and Director of Investor Relations, effective June 25, 2019. In this role, Silber will be responsible for leading financial strategies, including overseeing accounting, internal audit, investor relations and corporate communications. Silber will succeed Bengt Norvik, who will remain with the company until the end of June to ensure a smooth transition.

Dicot has signed an extended service agreement with Anthem Biosciences, Bangalore, India for preclinical developments of Libiguin™. Dicot has already since May 2017 collaborated with Anthem for development of chemical process steps for the production of Libiguin™. The new extended agreement includes both the toxicity tests required for regulatory approval of clinical trials of Libiguin™, and further optimizations of the chemical process steps for the manufacture of Libiguin™. The agreement assures Dicot the full intellectual property right of all developments by Anthem Biosciences regarding Libiguin™.